Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma. 真实世界证据支持Venetoclax作为t(11;14)骨髓瘤患者的额外选择。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-14 DOI: 10.1016/j.clml.2025.04.005
Jules Higué, Gaetan Basile, Titouan Cazaubiel, Julie Gay, Guillaume Béziat, Martin Gauthier, Miguel Carreiro, Noémie Gadaud, François Lifermann, Reza Tabrizi, Benjamin Hébraud, Miguel Granell, Léopoldine Lapierre, Pierre-Luc Mouchel, Pierre Bories, Jill Corre, Cyrille Hulin, Aurore Perrot
{"title":"Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma.","authors":"Jules Higué, Gaetan Basile, Titouan Cazaubiel, Julie Gay, Guillaume Béziat, Martin Gauthier, Miguel Carreiro, Noémie Gadaud, François Lifermann, Reza Tabrizi, Benjamin Hébraud, Miguel Granell, Léopoldine Lapierre, Pierre-Luc Mouchel, Pierre Bories, Jill Corre, Cyrille Hulin, Aurore Perrot","doi":"10.1016/j.clml.2025.04.005","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.005","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes. 含有达拉单抗(Dara)和来那度胺(Len)的四联体诱导治疗对新诊断的多发性骨髓瘤(NDMM)患者的干细胞动员产量:两个研究所的真实世界经验
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-11 DOI: 10.1016/j.clml.2025.04.003
Cindy Varga, Myra Robinson, Vikas Gupta, Craig C Hofmeister, Ajay K Nooka, Jonathan L Kaufman, Madhav V Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M Voorhees, Nisha S Joseph
{"title":"Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes.","authors":"Cindy Varga, Myra Robinson, Vikas Gupta, Craig C Hofmeister, Ajay K Nooka, Jonathan L Kaufman, Madhav V Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M Voorhees, Nisha S Joseph","doi":"10.1016/j.clml.2025.04.003","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.003","url":null,"abstract":"<p><strong>Background: </strong>Quadruplet therapy has become standard frontline therapy in transplant eligible NDMM patients. Using data from the MASTER and GRIFFIN trials, Chhabra et al. reported that Dara-Len containing quadruplet therapies had minimal impact on stem cell harvesting and engraftment. It is unclear if this remains true in a real-world setting where heterogeneity exists among patients and in institutional practices. Herein, we describe our experience of stem cell mobilization and collection in NDMM patients receiving DRVd at Levine Cancer Institute (LCI) and Emory Winship Cancer Institute.</p><p><strong>Methods: </strong>In this multi-center retrospective analysis, NDMM patients were eligible if they received DRVd and pursued stem cell collection between September, 2019 and January, 2024 at LCI and January, 2019 and July, 2022 at Emory. Patients either received 10 mcg/kg of growth colony-stimulating factor (G-CSF) daily (LCI) or 7.5 mcg/kg twice daily (Emory) for 4 days prior to collection and 1 dose on the morning of apheresis. Plerixafor was provided on day -1 of apheresis as a preemptive mobilization strategy at LCI and on an as needed basis at Emory. Patients with a suboptimal stem cell yield on day 1 received additional doses of G-CSF with or without rescue plerixafor at both sites followed by a second day of stem cell collection. Stem cell yield failure was defined as the inability to achieve a minimal goal dose of 2.0 × 10<sup>6</sup> cells/kg. Categorical outcomes were summarized with frequencies and proportions while numerical outcomes were summarized with descriptive statistics. Select data elements were only available in the LCI cohort.</p><p><strong>Results: </strong>A total of 423 patients were analyzed. The median patient age was 62 years (range, 23-79), and 38.1% of the cohort was African American. Thirteen percent of the cohort had high risk cytogenetics and 19.1% had ISS stage III disease. At LCI, patients received a median of 4 (range, 1-14) cycles of induction therapy before stem cell collection. In the entire cohort, 88.8% of patients received 21-day cycles and 11.2% received 28-day cycles. Most patients achieved a VGPR or better (87.2%) after induction and, of those with MRD data available at LCI, 41.6% (37 of 89) achieved MRD negative status (at 10<sup>-5</sup>). Of those with available data (n = 92), stem cell collection occurred after a median of 4 weeks (range, 2 to 8) from induction completion. All patients at LCI and 308 of the 318 (96.9%) patients at Emory received plerixafor. Among the entire cohort, the median number of total CD34+ cells collected was 9.0 × 10<sup>6</sup> CD34+ cells/kg (range 0-24.1). By institute, the median number of CD34+ cells across all attempts at LCI was 8.5 × 10<sup>6</sup> CD34+ cells/kg (range 2.9-18.1) and the median at Emory was 9.0 × 10<sup>6</sup> CD34+ cells/kg (0-24.1) indicating that there was no significant difference between mobilization strategies (P = .088). The","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma. 伊鲁替尼和Venetoclax治疗复发和难治性滤泡性淋巴瘤。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-11 DOI: 10.1016/j.clml.2025.04.004
Chaitra Ujjani, Hongkun Wang, Catherine Broome, Ajay K Gopal, Stephen D Smith, Catherine Lai, Mazyar Shadman, Lori Leslie, Edus H Warren, Ryan Lynch, Nicole Swanson, Trenton Grossfeld, Bruce D Cheson, Kieron Dunleavy
{"title":"Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.","authors":"Chaitra Ujjani, Hongkun Wang, Catherine Broome, Ajay K Gopal, Stephen D Smith, Catherine Lai, Mazyar Shadman, Lori Leslie, Edus H Warren, Ryan Lynch, Nicole Swanson, Trenton Grossfeld, Bruce D Cheson, Kieron Dunleavy","doi":"10.1016/j.clml.2025.04.004","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.004","url":null,"abstract":"<p><strong>Background: </strong>Bruton tyrosine kinase (BTK) inhibitors are approved in several B-cell malignancies, including the recent authorization of zanubrutinib for relapsed or refractory follicular lymphoma (FL).</p><p><strong>Methods: </strong>Based on preclinical studies demonstrating synergy with ibrutinib and the B-cell lymphoma (BCL)-2 inhibitor, venetoclax, in FL cell lines, we conducted a multicenter phase Ib/II study evaluating this combination in relapsed or refractory FL.</p><p><strong>Results: </strong>The recommended phase 2 dose was ibrutinib 560 mg and venetoclax 600 mg. There was no evidence of clinical tumor lysis syndrome, despite the omission of a venetoclax ramp up. At a median duration of therapy of 6 months, the most common adverse events were low grade diarrhea (83%), infection (75%), and rash (58%). Amongst the 24 patients enrolled, the overall and complete response (CR) rates were 63% and 21%. At a median follow up of 6.9 months, the median progression-free survival was 8.2 months, and the median duration of CR (n = 5) was 38 months.</p><p><strong>Conclusion: </strong>The combination of a BTK and BCL2 inhibitor is efficacious in relapsed/refractory FL and represents a unique dual-targeted approach warranting further investigation.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. Daratumumab用于新诊断的多发性骨髓瘤:来自GRIFFIN和PERSEUS的≥65岁患者的汇总分析。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-11 DOI: 10.1016/j.clml.2025.04.007
Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, Jacob Laubach, Hermann Einsele, Douglas W Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z Usmani, Paul G Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L Kaufman
{"title":"Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS.","authors":"Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, Jacob Laubach, Hermann Einsele, Douglas W Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z Usmani, Paul G Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L Kaufman","doi":"10.1016/j.clml.2025.04.007","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.007","url":null,"abstract":"<p><strong>Background: </strong>Older adults with newly diagnosed multiple myeloma (NDMM) have poor prognosis and constitute a subgroup of particular interest. In the GRIFFIN (NCT02874742) and PERSEUS (NCT03710603) studies, adding daratumumab to bortezomib/lenalidomide/dexamethasone (VRd) induction/consolidation and lenalidomide (R) maintenance deepened responses and improved progression-free survival (PFS) versus VRd/R in transplant-eligible patients with NDMM. Subgroup analyses of patients aged ≥65 years in PERSEUS demonstrated less pronounced PFS benefits (HRs: 0.97 [computerized algorithm]; 0.87 [independent review committee (IRC)]), potentially due to small event numbers, cytogenetic risk imbalances (high risk: D-VRd, 25.5%; VRd, 19.5%), and specific censoring rules. Here, we report results from a post hoc, pooled analysis of GRIFFIN and PERSEUS in patients aged ≥65 years (D-VRd, n = 122; VRd, n = 115).</p><p><strong>Methods: </strong>Using patient-level data, PFS analysis was evaluated per computerized algorithm in GRIFFIN and IRC in PERSEUS, stratified by International Staging System stage and cytogenetic risk, with no censoring of PFS events after ≥2 missing disease evaluations.</p><p><strong>Results: </strong>At a median follow-up of 49.6/47.5 months (GRIFFIN/PERSEUS), a trend in improved PFS was seen among patients aged ≥65 years favoring D-VRd (HR, 0.56 [95% CI, 0.30-1.01]). D-VRd improved rates of complete response or better (82.8% vs. 67.0%; OR, 2.37 [95% CI, 1.28-4.39]; P = .0046) and minimal residual disease negativity (10<sup>-5</sup>; 66.4% vs. 41.7%; OR, 2.75 [95% CI, 1.61-4.71]; P = .0002) versus VRd. No new safety concerns were identified.</p><p><strong>Conclusion: </strong>These data support use of D-VRd followed by D-R maintenance as standard of care for all transplant-eligible patients with NDMM, regardless of age up to 70 years.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. 双特异性抗体门诊用药模式的可行性和安全性:国际骨髓瘤学会第21届年会论文集。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-08 DOI: 10.1016/j.clml.2025.04.002
Sara A Scott, Danielle L Roberts, Vikas A Gupta, Nisha S Joseph, Craig C Hofmeister, Madhav V Dhodapkar, Sagar Lonial, Ajay K Nooka, Jonathan L Kaufman
{"title":"Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract.","authors":"Sara A Scott, Danielle L Roberts, Vikas A Gupta, Nisha S Joseph, Craig C Hofmeister, Madhav V Dhodapkar, Sagar Lonial, Ajay K Nooka, Jonathan L Kaufman","doi":"10.1016/j.clml.2025.04.002","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.002","url":null,"abstract":"<p><strong>Background: </strong>Teclistamab, elranatamab, and taqluetamab are T-cell redirecting bispecific antibodies (BsAbs) that gained accelerated approval for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). All 3 FDA labels suggest hospitalization for the step-up doses (SUDs) to monitor for CRS and ICANS.</p><p><strong>Methods: </strong>We implemented an institutional protocol to deliver SUD and target doses in the outpatient (OP) setting to minimize hospitalization and reimbursement burdens. Patient disease and social factors were evaluated for OP protocol eligibility. SUDs were administered on days 1, 4 and 8 preceded by acetaminophen, diphenhydramine, and dexamethasone. All patients received prophylactic tocilizumab per institutional protocol. From initiation of SUD #1 until 48-hours after the target dose, patients self-monitored temperature every 8 hours or in the setting of new signs or symptoms suggestive of CRS/ICANS. If fever or neurologic change should occur, patients were educated to take medications (acetaminophen 650 mg, diphenhydramine 50 mg and dexamethasone 20 mg) and present to the Immediate Care Center for assessment and management.</p><p><strong>Results: </strong>From 9/1/2023 to 8/31/2024, 52 patients received OP BsAb SUD. CRS occurred in 10 patients (19.2%, 9/10 events grade 1/2) and ICANS occurred in 3 patients (5.8%, grade 1). Four patients (7.7%) required hospitalization for toxicity management. All patients recovered from CRS and ICANS without additional toxicity.</p><p><strong>Conclusion: </strong>Implementation of this OP BsAb SUD protocol is feasible with acceptable risk of CRS/ICANS and hospitalization without compromising on safety. The low incidence of CRS/ ICANS with prophylactic tocilizumab and premedication and low hospitalization rates make this appealing for selected RRMM patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplanting Hope: Managing Relapsed/Refractory AML. 移植希望:治疗复发/难治性AML。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-08 DOI: 10.1016/j.clml.2025.04.001
Christopher Ronald Funk, Edmund K Waller
{"title":"Transplanting Hope: Managing Relapsed/Refractory AML.","authors":"Christopher Ronald Funk, Edmund K Waller","doi":"10.1016/j.clml.2025.04.001","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.001","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of myeloid precursor cells, with high relapse rates, particularly in patients who fail to achieve morphological remission after induction therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) can induce durable remissions through the graft-versus-leukemia (GVL) effect, yet current approaches of allo-HSCT often fail, with relapse rates of ∼40% within 6 months post-transplant. Outcomes following allo-HCT are inversely proportional to leukemia burden at the time of transplant. Both morphological relapse (≥5% blasts in the marrow) or minimal residual disease (MRD) positivity predict significantly reduced overall survival rates. Emerging strategies to improve outcomes in patients with high leukemic burden include aggressive bridging therapies (encompassing intensive salvage chemotherapy, hypomethylating agents, targeted inhibitors, and sequential induction-conditioning approaches such as FLAMSA), tailored conditioning regimens, post-transplant maintenance therapy, and innovative graft engineering methods. Graft engineering strategies, such as ORCA-T, which engineers stem cell grafts with a defined ratio of T-regulatory cells to effector T cells, are particularly promising and under evaluation in phase III clinical trials. These approaches aim to improve upon the poor outcomes for patients with persistent/relapsed AML undergoing allo-HCT.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review. 复发/难治性多发性骨髓瘤预后因素的重要性排序:国际医师小组在系统文献回顾后达成共识。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-03 DOI: 10.1016/j.clml.2025.03.013
Shaji Kumar, Xavier Leleu, Katja C Weisel, Rakesh Popat, Beatrice Suero, Samantha Craigie, Paul Spin, Leena Patel, Abril Oliva Ramirez, Christian Hampp, Wenzhen Ge, Qiufei Ma, Sundar Jagannath
{"title":"Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review.","authors":"Shaji Kumar, Xavier Leleu, Katja C Weisel, Rakesh Popat, Beatrice Suero, Samantha Craigie, Paul Spin, Leena Patel, Abril Oliva Ramirez, Christian Hampp, Wenzhen Ge, Qiufei Ma, Sundar Jagannath","doi":"10.1016/j.clml.2025.03.013","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.013","url":null,"abstract":"<p><strong>Purpose: </strong>The increasing use of single-arm and nonrandomized trial designs in oncology aims to expedite patient access to novel treatments. To contextualize their results using strategies such as external control arms or indirect treatment comparisons, prespecification of, and subsequent adjustment for, prognostic factors is required to ensure comparability of populations and avoid bias. This study aimed to systematically identify and rank prognostic factors relevant to treatment outcomes in patients with relapsed/refractory multiple myeloma (RRMM).</p><p><strong>Materials and methods: </strong>To comprehensively identify prognostic factors, a systematic literature review was conducted with databases searched between January 2016 and April 2022. Clinical studies enrolling adult patients with RRMM and assessing prognostic significance using adjusted analyses were included. Subsequently, an international panel of multiple myeloma experts confirmed and ranked these variables by their importance in predicting clinical outcomes. A structured series of expert consultations was conducted from November 2022 to February 2023, including 2 rounds of consensus meetings.</p><p><strong>Results: </strong>Of 125 studies included in the systematic literature review, 112 described 97 factors significantly associated with at least 1 outcome of interest. A total of 25 factors associated with overall survival and/or objective response and reported in at least 2 studies were included in the ranking process. The physician panel unanimously agreed on the 6 most important prognostic factors: cytogenetic risk, age, refractory status, disease stage, performance status, and extramedullary disease/plasmacytoma.</p><p><strong>Conclusion: </strong>This list of RRMM prognostic factors can be used in comparative analyses to assess treatment effectiveness in the absence of head-to-head trials.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. BR与rchop样方案治疗滤泡性淋巴瘤患者实际预后的比较
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-03 DOI: 10.1016/j.clml.2025.03.017
Kelsey Baron, Eric Anto, John Esther, Victoria A Vardell, Lisa Pappas, Allison Bock, Daniel A Ermann, Lindsey A Fitzgerald, Boyu Hu, Harsh R Shah
{"title":"Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens.","authors":"Kelsey Baron, Eric Anto, John Esther, Victoria A Vardell, Lisa Pappas, Allison Bock, Daniel A Ermann, Lindsey A Fitzgerald, Boyu Hu, Harsh R Shah","doi":"10.1016/j.clml.2025.03.017","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.017","url":null,"abstract":"<p><strong>Background: </strong>Patients with follicular lymphoma (FL) grade (G) 1-3A who meet treatment criteria are commonly treated with chemo-immunotherapy regimens such as bendamustine plus rituximab (BR) or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP). Two prospective trials have compared BR to RCHOP-like regimens and showed improved progression free survival with BR in FL G1-2 patients. However, in real-world practice, there is clinical variability in utilization of BR versus RCHOP-like regimens. Additionally, the optimal treatment for patients with FL G3A remains unclear.</p><p><strong>Methods: </strong>We used a nationwide electronic health record-derived de-identified database to compare outcomes in 2089 patients with FL G1-3A treated with frontline BR versus RCHOP-like regimens.</p><p><strong>Results: </strong>We demonstrated clinical improvement in time to next treatment or death (TTNTD) with BR (median 96 vs. 78 months, HR 1.15, 95% CI 0.986-1.332, P = .086), albeit not statistically significant. No difference in overall survival (OS) was observed. Maintenance rituximab was associated with improved TTNTD and OS. Among G3A patients (N = 304), TTNTD was comparable between the 2 regimens, however OS was significantly improved with RCHOP-like regimens in univariate analysis (median 138 vs. 96 months, HR 0.51, 95% CI 0.313-0.834, P = .007).</p><p><strong>Conclusions: </strong>In conclusion, this study of real-world patients supports the use of BR and rituximab maintenance for front-line treatment of FL. Further prospective studies are needed to determine the ideal treatment for FL G3A.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic Strategies. SOHO最新动态和下一个问题。非典型慢性髓系白血病:发病机制、诊断挑战和治疗策略。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-03-29 DOI: 10.1016/j.clml.2025.03.015
Alessandro Costa, Massimo Breccia
{"title":"SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic Strategies.","authors":"Alessandro Costa, Massimo Breccia","doi":"10.1016/j.clml.2025.03.015","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.015","url":null,"abstract":"<p><p>Atypical chronic myeloid leukemia (aCML) is a rare and challenging clonal hematopoietic disorder within the myelodysplastic/myeloproliferative neoplasm (MDS/MPN) spectrum. Over the past two decades, substantial progress has been made in understanding the genetic mechanisms driving aCML, revealing a complex and heterogeneous mutational landscape. Key ancestral mutations, such as ASXL1 and ETNK1, have been identified, providing a foundation for the pathogenesis and for the possible emergence of secondary abnormalities, particularly in epigenetic regulation (eg, SETBP1), and in splicing process (eg, SRSF2). These molecular insights have been integrated into current diagnostic classifications, refining disease characterization and offering potential targets for precision therapies. Despite these advances, significant clinical challenges persist due to the disease's rarity and the lack of randomized clinical trials. Therapeutic strategies remain inadequately defined, with allogeneic stem cell transplantation being the only curative option. This review provides an overview of the molecular, clinical, and therapeutic information that may pave the way for essential advancements in the proper management of this disease.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy. 临床医生的观点和荧光原位杂交(FISH)定义多发性骨髓瘤细胞遗传学风险的方法学应用:一份来自意大利欧洲骨髓瘤网络(EMN)的真实世界调查报告。
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-03-29 DOI: 10.1016/j.clml.2025.03.011
Lorenzo Cani, Maria Teresa Petrucci, Katia Mancuso, Renato Zambello, Laura Paris, Sara Aquino, Flavia Lotti, Francesco Vassallo, Norbert Pescosta, Micol Quaresima, Patrizia Tosi, Iolanda Donatella Vincelli, Sonia Ronconi, Nicola Giuliani, Francesco Pisani, Mario Luppi, Rita Rizzi, Rita Mazza, Delia Rota-Scalabrini, Claudia Cellini, Silvia Mangiacavalli, Giuseppe Pietrantuono, Maria Luisa Pioltelli, Antonietta Pia Falcone, Elisabetta Antonioli, Angelo Belotti, Sonia Morè, Benedetto Bruno, Mario Boccadoro, Mattia D'Agostino
{"title":"Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.","authors":"Lorenzo Cani, Maria Teresa Petrucci, Katia Mancuso, Renato Zambello, Laura Paris, Sara Aquino, Flavia Lotti, Francesco Vassallo, Norbert Pescosta, Micol Quaresima, Patrizia Tosi, Iolanda Donatella Vincelli, Sonia Ronconi, Nicola Giuliani, Francesco Pisani, Mario Luppi, Rita Rizzi, Rita Mazza, Delia Rota-Scalabrini, Claudia Cellini, Silvia Mangiacavalli, Giuseppe Pietrantuono, Maria Luisa Pioltelli, Antonietta Pia Falcone, Elisabetta Antonioli, Angelo Belotti, Sonia Morè, Benedetto Bruno, Mario Boccadoro, Mattia D'Agostino","doi":"10.1016/j.clml.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.011","url":null,"abstract":"<p><strong>Background: </strong>Fluorescence in situ hybridization (FISH) is the standard technique for the prognostic detection of cytogenetic abnormalities (CA) in multiple myeloma (MM). In Italy, the application of practical guidelines for FISH testing in clinical studies and the degree of standardization of laboratory techniques are largely unknown.</p><p><strong>Methods: </strong>We conducted a survey from April to July 2023 among 70 MM-treating centers associated with the European Myeloma Network Italy and geographically well distributed across Italy. We aimed to record laboratory and clinicians' perspectives about FISH application in Italy, with a focus on 1q alterations.</p><p><strong>Results: </strong>FISH was widely accessible across the country, with 71% of centers performing it locally, while the remaining centers (predominantly those with <30 newly diagnosed MM cases/year) sent samples to external laboratories. Variability in laboratory techniques, such as CD138<sup>+</sup> cell purification and CA detection thresholds, was observed among centers. The centers analyzed del(17p) (100%), t(4;14) (100%), t(14;16) (98%), 1q+ (96%, with 70% distinguishing between gain and amplification), t(11;14) (90%), del(1p32) (88%), del(13q) (68%), and hyperdiploidy (52%). FISH emerged as a crucial prognostic technique, since 94% of centers used the Revised International Staging System (R-ISS) at diagnosis, and 69% implemented the recent R2-ISS. Most centers performed FISH at diagnosis in all patients, while others did not routinely perform FISH in some categories of patients (e.g., aged >80 years). At relapse, 53% of centers routinely repeated FISH testing, 9% did not, while others repeated it selectively.</p><p><strong>Conclusions: </strong>This overview of FISH use in Italy provides a basis for future standardization efforts.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信